Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
about
Heparin versus placebo for non-ST elevation acute coronary syndromesEarly invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraHeparin versus placebo for acute coronary syndromesLow molecular weight heparins versus unfractionated heparin for acute coronary syndromesArterial indications for the low molecular weight heparinsRoutine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraAdministration of low molecular weight and unfractionated heparin during percutaneous coronary interventionEnoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiencyClinical use of new antithrombotic therapies for medical management of acute coronary syndromesA critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery diseasePotential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplastyUnstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapyNon-inferiority and networks: inferring efficacy from a web of data.Dosing and monitoring of low-molecular-weight heparins in special populations.The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinLow molecular weight heparins in acute ischaemic syndromes.New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.Low-molecular-weight heparins: pharmacoeconomic decision modeling based on meta-analysis data.Clinical trials of low-molecular-weight heparins in cardiology.Low-molecular-weight heparins for acute coronary syndromes: an emergency medicine perspective.New advances in the management of acute coronary syndromes: 1. Matching treatment to risk.Therapy of unstable angina with the low molecular weight heparins.Low molecular weight heparins for arterial thrombosis.Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris.Recent advances in the management of unstable angina and non-Q-wave myocardial infarctionRole of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Management of acute coronary syndrome.Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry.Low-molecular-weight heparins for acute coronary syndromes.Heparin should be administered to every patient admitted to the hospital with possible unstable angina.Low molecular weight heparins (enoxaparin) in the management of unstable angina: the TIMI studies. Thrombolysis in Myocardial Infarction.Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice.
P2860
Q24193744-F7BC0EDB-99C4-4C0B-8E93-8984FD1DED1DQ24236794-A01AF2F5-6142-44CC-BC51-F9D56AE7199EQ24243000-8EB17798-E08D-4009-A61C-733AE2696528Q24250287-B4ECA1AF-9502-43C1-BE81-F6D257B2E9CDQ24806932-79D8CE96-1417-4AAD-973E-F08E016FC955Q26471900-2715DC49-A297-4B51-AB7B-93848A4E977FQ26748752-163D7E74-A7A2-4C44-BB52-8065F303917EQ28175651-D3B3B74A-6CA2-4268-9E18-11752A82EF84Q28177271-08A546E6-49B1-42FD-BC67-BAE27916D7FFQ28186283-5DC8B498-746F-47C9-BB56-4E733221379AQ28190541-9F22EAD4-1DAA-4DE6-8AC6-865CF1277C70Q28192025-634A9F5E-1F23-4A75-87B6-79011A796500Q31030399-CEF585D4-F905-4864-96C7-C864BD86A314Q32049893-8D59C007-D6EB-4FB2-9803-58F7A063CFE6Q33357627-88570C7E-5DA6-4FB2-8CB2-E5470821F4ECQ33381356-2AE021B5-0290-4951-BB75-0224BBC34657Q33503951-24511940-636F-410D-8CB6-01546BDD860DQ33576224-AEEB4677-1524-4FC7-BB85-4EA3E0A8CBE1Q33618610-D42F12ED-270A-4CAD-AA58-3040715911EDQ33803411-98EEA0FD-D8AD-43A9-9E02-CB4E2643124EQ33803415-EFDDAD65-0527-4E8E-BE5D-423262D5AA9DQ33955730-77CD2136-B5C4-43DE-BFD1-890818931F30Q34158934-9D352817-F2A4-416C-BCA6-C3FD093DA668Q34158943-D7724EEE-C59F-4139-A3D1-E56C249234A3Q34415964-0400B29F-B384-4046-A978-C8BD1C7E7E29Q34445660-BBC8EE42-ACBD-4FA3-B835-3AAFACE7186CQ35590045-324C8497-9DFA-4C37-99BE-F13CCCC08D06Q35803300-740031A6-BCC4-4900-99F2-449D4513F724Q35944733-472FA779-E9EB-4E55-96A2-CD39679DF6E7Q36363183-2F56DFC0-8960-4D4D-BED6-692F5F331567Q37223676-96350E70-96F6-4BD8-AEAF-80BCD88D1B81Q37417274-C134F66D-6411-4E0D-8EBF-DAF144E0782DQ41707230-7166ADF7-C420-4A5F-8F0E-20989DE731E7Q42711606-84C743C0-0F25-4FB2-9A73-29F964176448Q43018603-8BB536DD-A6F3-419D-BE92-A878CC592928Q47336952-B62A55D4-5A05-40DB-9EAC-CACA2351265A
P2860
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Low molecular weight heparin v ...... le angina and silent ischemia.
@en
type
label
Low molecular weight heparin v ...... le angina and silent ischemia.
@en
prefLabel
Low molecular weight heparin v ...... le angina and silent ischemia.
@en
P2093
P1476
Low molecular weight heparin v ...... le angina and silent ischemia.
@en
P2093
Duronto EA
Gurfinkel EP
P304
P356
10.1016/0735-1097(95)80001-W
P407
P577
1995-08-01T00:00:00Z